THE LANCET - Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis

THE LANCET - Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis

Hydroxychloroquine or chloroquine, often in combination with a second-generation macrolide, are being widely used for treatment of COVID-19, despite no conclusive evidence of their benefit. Although generally safe when used for approved...
NEJM - Remdesivir for the Treatment of Covid-19 — Preliminary Report

NEJM - Remdesivir for the Treatment of Covid-19 — Preliminary Report

The New England Journal of MedicineAlthough several therapeutic agents have been evaluated for the treatment of coronavirus disease 2019 (Covid-19), none have yet been shown to be efficacious.
JAMA - Use of Prone Positioning in Nonintubated Patients With COVID-19 and Hypoxemic Acute Respiratory Failure

JAMA - Use of Prone Positioning in Nonintubated Patients With COVID-19 and Hypoxemic Acute Respiratory Failure

JAMA NetworkPatients with coronavirus disease 2019 (COVID-19) are at risk for acute respiratory distress syndrome. In intubated patients with severe acute respiratory distress syndrome, early and prolonged (at least 12 hours daily) prone...
JAMA - Respiratory Parameters in Patients With COVID-19 After Using Noninvasive Ventilation in the Prone Position Outside the Intensive Care Unit

JAMA - Respiratory Parameters in Patients With COVID-19 After Using Noninvasive Ventilation in the Prone Position Outside the Intensive Care Unit

JAMA NetworkThe pandemic of coronavirus disease 2019 (COVID-19), with a large number of patients requiring respiratory support, threatens to overload intensive care units (ICUs). Noninvasive ventilation (NIV) use in general wards may be an...
JAMA - Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State

JAMA - Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State

JAMA Network

Among patients with coronavirus disease 2019 (COVID-19), is there an association between use of hydroxychloroquine, with or without azithromycin, and in-hospital mortality?

THE LANCET - Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients

THE LANCET - Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients

Effective antiviral therapy is important for tackling the coronavirus disease 2019 (COVID-19) pandemic. We assessed the efficacy and safety of combined interferon beta-1b, lopinavir–ritonavir, and ribavirin for treating patients with COVID-19.
WHO - COVID-19 and the use of angiotensin-converting enzyme inhibitors and receptor blockers

WHO - COVID-19 and the use of angiotensin-converting enzyme inhibitors and receptor blockers

Worl Health OrganizationConcerns exists that angiotensin-converting enzyme inhibitors (ACE inhibitors) and angiotensin receptor blockers (ARBs)increase susceptibility to coronavirus SARS CoV-2 (the viral agent that causes the disease COVID-19)...
NEJM - Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19

NEJM - Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19

The New England Journal of Medicine

Hydroxychloroquine has been widely administered to patients with Covid-19 without robust evidence supporting its use.

THE LANCET - Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial

THE LANCET - Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial

No specific antiviral drug has been proven effective for treatment of patients with severe coronavirus disease 2019 (COVID-19). Remdesivir (GS-5734), a nucleoside analogue prodrug, has inhibitory effects on pathogenic animal and human...
NEJM - Covid-19 — A Reminder to Reason

NEJM - Covid-19 — A Reminder to Reason

The New England Journal of MedicineHow long will this pandemic last? When will we find a treatment or vaccine? Which drug should we give our patients? Will we run out of personal protective equipment (PPE)? When will everyone return to work? We...
NIH - COVID-19 Treatment Guidelines

NIH - COVID-19 Treatment Guidelines

National Institutes of HeatlhThese Treatment Guidelines have been developed to inform clinicians how to care for patients with COVID-19. Because clinical information about the optimal management of COVID-19 is evolving quickly, these Guidelines...
JAMA - Management of COVID-19 Respiratory Distress

JAMA - Management of COVID-19 Respiratory Distress

JAMA NETWORKAcute respiratory distress syndrome (ARDS) can originate from either the gas or vascular side of the alveolus. Although the portal for coronavirus disease 2019 (COVID-19) is inhalational, and alveolar infiltrates are commonly found on...
JAMA - Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection

JAMA - Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection

JAMA NETWORK

How safe and effective are 2 different regimens of chloroquine diphosphate in the treatment of severe coronavirus disease 2019 (COVID-19)?

WHO - The use of non-steroidal anti-inflammatory drugs (NSAIDs) in patients with COVID-19

WHO - The use of non-steroidal anti-inflammatory drugs (NSAIDs) in patients with COVID-19

World Health OrganizationNon-steroidal anti-inflammatory drugs (NSAIDs) are among the most commonly used drugs, and have a wide range of uses. NSAIDs include nonselective cyclooxygenase (COX) inhibitors (such as ibuprofen, aspirin...
NEJM - Compassionate Use of Remdesivir for Patients with Severe Covid-19

NEJM - Compassionate Use of Remdesivir for Patients with Severe Covid-19

The New England Journal of Medicine

Remdesivir, a nucleotide analogue prodrug that inhibits viral RNA polymerases, has shown in vitro activity against SARS-CoV-2.

12345
Eventos
«junho de 2023»
segterquaquisexsábdom
2930311234
567891011
12131415161718
19202122232425
262728293012
3456789
Categorias

Categorias

Arquivo de Notícias

Arquivo